Cantor Fitzgerald Reaffirms “Overweight” Rating for Nyxoah (NASDAQ:NYXH)

Nyxoah (NASDAQ:NYXH)‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $11.00 price target on the stock. Cantor Fitzgerald’s price target points to a potential upside of 257.14% from the stock’s current price.

Other analysts also recently issued reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nyxoah in a research report on Monday, December 29th. Stifel Nicolaus dropped their price objective on shares of Nyxoah from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $11.25.

Nyxoah Trading Down 0.3%

NASDAQ NYXH opened at $3.08 on Monday. The firm has a market capitalization of $119.38 million, a PE ratio of -1.15 and a beta of 1.56. The stock’s 50 day moving average is $4.33 and its 200 day moving average is $4.83. Nyxoah has a twelve month low of $3.02 and a twelve month high of $11.87. The company has a quick ratio of 1.16, a current ratio of 1.25 and a debt-to-equity ratio of 0.37.

Nyxoah (NASDAQ:NYXH) last posted its quarterly earnings data on Thursday, March 19th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.03). The firm had revenue of $6.62 million during the quarter, compared to the consensus estimate of $5.70 million. Nyxoah had a negative return on equity of 139.18% and a negative net margin of 884.69%. Research analysts forecast that Nyxoah will post -1.91 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of NYXH. Raymond James Financial Inc. lifted its holdings in shares of Nyxoah by 35.6% during the third quarter. Raymond James Financial Inc. now owns 12,762 shares of the company’s stock valued at $59,000 after purchasing an additional 3,353 shares in the last quarter. Bank of America Corp DE increased its holdings in Nyxoah by 72.4% in the 2nd quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock worth $59,000 after buying an additional 3,303 shares in the last quarter. Citadel Advisors LLC purchased a new position in Nyxoah in the 3rd quarter worth about $98,000. Deutsche Bank AG raised its position in Nyxoah by 40.0% in the 4th quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock worth $161,000 after buying an additional 10,000 shares during the last quarter. Finally, Shay Capital LLC bought a new position in Nyxoah during the 2nd quarter valued at about $374,000.

Nyxoah Company Profile

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.